Analysis of the cytosolic content of the pS2 protein in breast cancer;Análisis del contenido citosólico de la proteína pS2 en el cáncer de mama

Revista Espanola de Medicina Nuclear

Volumn 21, Issue 1, 2002, Pages 28-33

  Tamargo, F ^a   Vizoso, F ^a   Lamelas, M L ^a   Rodil, A ^a   Verez P ^a   Raigoso, P ^b   Mulero, M ^a   Vazquez J ^a   Roiz, C ^b   Allende, Ma Teresa ^b  

^a HOSPITAL DE JOVE   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Breast cancer; Estrogen receptors; Progesterone receptors; pS2

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN PS2; ESTROGEN; PROGESTERONE; PROTEIN; TFF1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOSOL; DISEASE MARKER; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; PREMENOPAUSE; PROGNOSIS; PROTEIN EXPRESSION; BREAST TUMOR; CHEMISTRY; EVALUATION; LYMPH NODE METASTASIS; MENOPAUSE; NEOPLASM; PAGET NIPPLE DISEASE; PATHOLOGY; RADIOIMMUNOASSAY;

ADULT; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL DIFFERENTIATION; CYTOSOL; ESTROGENS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MENOPAUSE; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; PROGESTERONE; PROGNOSIS; PROTEINS; RADIOIMMUNOASSAY; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 0036479469     PISSN: 02126982     EISSN: 1578200X     Source Type: Journal    
DOI: 10.1016/s0212-6982(02)72029-6     Document Type: Article

References (25)

1. Masiakovski P, Breathnach R, Bloch J, Gannon F, Krust A, Chambon P. Cloning of cDNA sequences of hormone -regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res 1982;10:7895-7903.
2. Río MC, Bellocq JP, Daniel JT, Tomasetto C, Lathe R, Chenard MP, et al. Breast cancer-associated pS2 protein: synthesis and secretion by normal stomach mucose. Science 1988;241:705-708.
3. Luqmani Y, Bennett C, Paterson I, Corbishley CM, Rio MC, Chambon P, et al. Expression of the pS2 gene in normal, benign and neoplasic human stomach. Int J Cancer 1989;44:806-812.
4. Pallaud C, Le Doussal V, Pichon MF, Prud'Homme JF, Hacene K, Milgrom E. Immunohistochemistry of pS2 in normal human breast and in various histological forms of breast tumours. Histo-pathology 1993;23:249-256.
5. Hähnel E, Robbins P, Háhnel R. Expression of the pS2 gene in normal breast tissue. Breast Cancer Res Treat 1993;28:295-297.
6. Jakolev S, Breathnach R, Jeltsch J, Masiakowski P, Chambon P: Sequence of pS2 mRNA induced by estrogen in the human breast cancer cell line. Nucleic Acids Res 1984;12:2861-2878.
7. Henry JA, Piggott NH, Mallick UK, Nicholson S, Farndon JR, Westley BR, et al. pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with pronostic factors and endocrine response. Br J Cancer 1991;63:615-622.
8. Foekens JA, Río MC, Seguin P, Van Putten WLJ, Fauque J, Nap M, et al. Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res 1990;50:3832-3837.
9. Predine J, Spyratos F, Prud'Homme JF, Andrieu C, Hacene K, Brunet M, et al. Enzyme-linked immunosorbent assay of pS2 in breast cancers, benign tumours and normal tissues. Cancer 1992;69:2116-2123.
10. Schwartz LH, Koerner FC, Esgerton SM, Sawicka JM, Río MC, Bellocq JP, et al. pS2 expression and response to hormonal therapy in patients with advanced breast cancer. Cancer Res 1991;51:624-628.
11. Foekens JA, Portengen H, Look MP, Van Putten WLJ, Thirion B, Bontenbal M, et al. Relationship of pS2 with response to tamoxifen therapy in patients with recurrent breast cancer. Br J Cancer 1994;70:1217-1223.
12. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957;11:359-377.
13. Goussard I, Lechevrel C, Roussel G, Cren H, Bera O, Sala M. Immunoradiometric assay of pS2 protein in breast cancer cytosols. Clin Chim Acta 1991;37:1759-1762.
14. Gion M, Mione R, Pappagallo GL, Gatti C, Nascimben O, Bari M, et al. pS2 in breast cancer-alternative or complementary tool to steroid recertor status? Evaluation of 446 cases. Br J Cancer 1993;68:374-379.
15. Correale M, Abatte A, Paradiso A, Schittulli F, Dragone CD, Tedone T, et al. pS2 a new cytosolic protein recognised by monoclonal antibodies as a marker of hormone sensitivity in breast cancer. Cell Biophys 1993;22:101-110.
16. Besse G, Kwiatkowski F, Gaillard G, Daves A, Dalifard I, Basuyan JP, et al. pS2 as a prognostic factor in 1,065 cases of human breast cancer. A multicenter study. Bull Cancer 1994;81:289-296.
17. Speiser P, Stolzlechner J, Haider K, Heinzl H, Jakesz R, Pecherstorfer M, et al. pS2 protein status fails to be an independent prognostic factor in average breast cancer population . Anticancer Res 1994;14:2125-2130.
18. Luqmani Y, Temmin L, Memon A, Parkar A, Aly M, Motawy M, et al. Immunoradiometric measuremnet of pS2 in breast cancer. Act Oncol 1999;38:805-814.
19. Spyratos F, Martin PM, Hacène K, Andrieu C, Romain S, Floiras JL, et al. Prognostic value of a solubilized fraction of EGF receptors in primary breast cancer using an immunoenzymatic assay - a retrospective study. Breast Cancer Res Treat 1994;29:85-95.
20. Gillesby BE, Zacharewski TR. pS2 (TFF 1) levels in human breast cancer tumor samples: correlation with cllinical and histological prognostic markers. Breast Cancer Res Treat 1999;56:253-265.
21. Soubeyran I, Wafflart J, Bonichon F, De Mascarel I, Trojani M, Durand M, et al. Immunohistochemical determination of pS2 in invasive breast carcinomas: a study on 942 cases. Breast Cancer Res Treat 1995;34:119-128.
22. Horiguchi J, Lino Y, Takei H. Expression of pS2 estrogen-inducible protein in primary breast cancer. Oncology 1996;53:12-15.
23. Elledge RM, Green S, Pugh R, Allred DC, Clark GM, Hill J, et al. Estrogen receptor and progesterone receptor, by ligand-binding assay compared with ER, PR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic brast cancer: a southwest oncology group study. Int J Cancer (Pred. Oncol.) 2000;89:111-117.
24. Río MC, Bellocq JP, Gairard B. Specific expression of the pS2 gene in subclasses of breast cancers in comparision with expression of the estrogen and progesterone receptors and the oncogene erbB2. Proc Natl Acad Sci Usa 1987;84:9243-9247.
25. Núnez AM, Berry M, Imler J, Chambon P. The 5′Flanking region of the pS2 gene contains a complex enhancer region responsive to oestrogens, epidermal growth factor, a tumour pro-